Jefferies Cuts Artiva Biotherapeutics to Hold From Buy
Jefferies cut its rating on Artiva Biotherapeutics to Hold from Buy. A $4.00-per-share price target was also announced.
Related stories
AMD, Nvidia, Micron and Arm shares fall
AMD fell 6.5%, Nvidia 2.5%, Micron 3.7% and Arm 7.5%.
M impact | EQUITY | Oct 30, 2026, 08:59 AM UTC
BlackRock Raises Combined Stake in Tryg Above 5%
BlackRock's combined holding in Tryg has risen above 5%.
M impact | EQUITY | Oct 30, 2026, 08:59 AM UTC
Jiangxi Copper falls more than 6% again intraday
M impact | EQUITY | Oct 30, 2026, 08:57 AM UTC
Court Accepts Bankruptcy Liquidation Application Against CNG Weihai
A court accepted a bankruptcy liquidation application against CNG Weihai on Oct. 29, 2026.
M impact | EQUITY | Oct 30, 2026, 08:56 AM UTC
FOKUS 3-BP Reports Record Third-Quarter Profit
M impact | EQUITY | Oct 30, 2026, 08:51 AM UTC
BP reports record $8.46 billion third-quarter profit, beats forecasts
M impact | EQUITY | Oct 30, 2026, 08:49 AM UTC